AC Immune Shares Surge 25% Following Bright Interim Parkinson's Trial Results
I'm PortAI, I can summarize articles.
AC Immune's shares surged 25% after promising interim results from its Phase 2 Parkinson's trial. The experimental therapy ACI-7104.056 met all immunogenicity goals with a 100% responder rate. Key biomarkers remained stable, suggesting potential disease stabilization. The treatment showed no significant safety issues. AC Immune plans to engage regulators for fast-tracking development. The market is optimistic about therapies targeting underlying disease processes, with implications beyond Parkinson's. The company's future steps will be crucial in proving long-term benefits and regulatory acceptance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Stock Invest The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments